Contineum Therapeutics (CTNM) Expected to Announce Earnings on Wednesday

Contineum Therapeutics (NASDAQ:CTNM) is expected to release its earnings data before the market opens on Wednesday, February 26th. Analysts expect Contineum Therapeutics to post earnings of ($0.44) per share for the quarter.

Contineum Therapeutics Price Performance

Shares of CTNM opened at $7.64 on Tuesday. Contineum Therapeutics has a 1-year low of $7.04 and a 1-year high of $22.00. The company’s fifty day moving average price is $11.43 and its 200-day moving average price is $15.06.

Analyst Upgrades and Downgrades

Separately, Royal Bank of Canada reissued an “outperform” rating and set a $31.00 price objective on shares of Contineum Therapeutics in a report on Thursday, January 9th. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $29.25.

Contineum Therapeutics Company Profile

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).